Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entire COX-2 Class Is TARGET Of Critical Lancet Editorial

This article was originally published in The Pink Sheet Daily

Executive Summary

The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.
Advertisement

Related Content

FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says
FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says
Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004
Merck Arcoxia User Fee Date Is Nov. 13; Schering’s Late Fees For Zetia Delay Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS060331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel